The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 3.80 (8.44%)
Spread: 1.00 (2.083%)
Open: 45.00
High: 48.80
Low: 45.60
Prev. Close: 45.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Wed, 14th Jul 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Symphony Environmental Technologies, up 11% at 21.17 pence, 12-month range 10.65p-47.0p. The anti-microbial plastic technologies firm receives approval from the US Food & Drug Administration for its d2p antimicrobial food contact technology.

----------

88 Energy, up 7.9% at 1.89p, 12-month range 0.24p-4.70p. The Alaska-focused oil exploration and appraisal company says additional phase one geochemical analysis of fluid extracts from Merlin-1 well core samples again demonstrates the presence of hydrocarbons. Results from phase two of side-wall core trim analysis are expected in the next few weeks. Phase two is designed to confirm not only the presence of oil but also the nature of the source rock, to help understand the likely quality of the oil as well as migration pathways.

----------

Alpha FX Group, up 6.7% at 1,665.00p, 12-month range 677p-1,720p. The foreign exchange risk management and international payments firm says trading in the first half ended June 30 has been "strong" across its business, with revenue up 89% year on year at GBP34 million. Adds 84 new clients and notes average revenue per client continued to increase. The company expects to exceed current internal expectations for 2021, on the back of continued strong trading. In 2020, saw revenue of GBP46.2 million with pretax profit of GBP17.1 million.

----------

Avacta, up 5.9% at 143.56p, 12-month range 88.66p-291.80p. The developer of diagnostics and cancer therapies says Life Sciences unit gets ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

----------

Fulcrum Utility Services, up 5.6% at 32.74p, 12-month range 28.25p-43.60p. The energy and multi-utility services provider wins new GBP4.9 million multi-utility infrastructure contract from unnamed "large investor developer", for a "major" new employment park in the West Midlands. As part of the contract, the company will design and install a high voltage primary substation and the electricity, water, and gas infrastructure to "energise and power" the new development.

----------

AIM - LOSERS

----------

Tern, down 13% at 19.40p, 12-month range 5.50p-31.67p. The investment firm completes fundraise at the issue price of 18.8p per share. The retail offer and subscription were both oversubscribed and the company said it raised GBP2 million and GBP4 million, respectively. "We intend to utilise the proceeds to maximise the value to our shareholders of our portfolio, and I look forward to providing further updates in due course," says Chief Executive Al Sisto.

----------

Kromek Group, down 7.0% at 15.00p, 12-month range 7.66p-25.20p. The detection technology firm says revenue totalled GBP10.4 million for the financial year that ended April 30 versus GBP13.1 million the year before. Pretax loss, however, narrows to GBP6.3 million from GBP18.3 million loss the year prior. This is due to non-repeat of GBP13.1 million of exceptional impairment losses on trade receivables and amounts recoverable on contracts. Separately, Kromek says it wins new contracts and orders across all segments for delivery this year.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Read more
18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

Read more
18 Jan 2022 13:52

Avacta selects potential tumour treatment for preclinical development

Avacta selects potential tumour treatment for preclinical development

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
10 Jan 2022 12:16

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Read more
10 Jan 2022 12:08

Abingdon Health plunges after Avacta stops selling Covid-19 test

Abingdon Health plunges after Avacta stops selling Covid-19 test

Read more
10 Jan 2022 11:29

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Read more
10 Jan 2022 11:05

Shares plummet as Avacta pauses sale of lateral flow tests

(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.

Read more
10 Jan 2022 09:20

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 11:28

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Read more
22 Dec 2021 10:31

Avacta shares up as flow tests receive CE mark for self-test use

Avacta shares up as flow tests receive CE mark for self-test use

Read more
15 Dec 2021 11:56

Avacta confirms lateral flow tests can detect Omicron variant

Avacta confirms lateral flow tests can detect Omicron variant

Read more
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.